Permanent renal loss following tumor necrosis factor α antagonists for arthritis

Tzu Jen Chen, Ya Fei Yang, Po Hao Huang, Hsin Hung Lin*, Chiu Ching Huang

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

6 Scopus citations

Abstract

Tumor necrosis factor α (TNF-α) antagonists are now widely used in the treatment of aggressive rheumatoid arthritis and are generally well tolerated. Although rare, they could induce systemic lupus erythematosus, glomerulonephritis, and antineutrophil cytoplasmic antibody associated systemic vasculitis. Tumor necrosis factor α antagonists associated glomerulonephritis usually subsides after discontinuation of the therapy and subsequent initiation of corticosteroids and immunosuppressive agents. Here we describe crescentic glomerulonephritis progression to end-stage renal disease in a patient following two doses of TNF-α antagonists for the treatment of reactive arthritis. To our knowledge, dialysis dependent permanent renal loss after TNF-α antagonists has not yet been reported. We suggest the renal function should be closely monitored in patients treated with TNF-α antagonists by rheumatologists.

Original languageEnglish
Pages (from-to)1077-1079
Number of pages3
JournalRheumatology International
Volume30
Issue number8
DOIs
StatePublished - 06 2010
Externally publishedYes

Keywords

  • Adalimumab
  • Glomerulonephritis
  • Renal failure
  • TNF-α antagonists

Fingerprint

Dive into the research topics of 'Permanent renal loss following tumor necrosis factor α antagonists for arthritis'. Together they form a unique fingerprint.

Cite this